Source your next deep tech deal with the Polsky Center. Join us on Wednesday, January 19, 2022 from 1:00–5:00 p.m. CT, to hear from Cohort 3 graduates of the Compass, the Polsky Center’s Compass deep tech accelerator. In this virtual demo day, each team will pitch to a panel of esteemed judges with curated Q&A from the audience.

• 4SR Biosciences has developed technology that uses next-gen sequencing to study tRNAs at higher throughput and greater resolution. In addition to quantifying tRNA expression, this technology can simultaneously measure charging (amino acylation), post-transcriptional modifications, fragmentation, and coexpression with other small RNAs. 4SR Biosciences aims to develop a tRNA-based biomarker screening platform for diagnostic and therapeutic innovations. They have recently been accepted into the prestigious Illumina Accelerator in the San Francisco Bay area.
• AIccelerate uses proprietary software to convert ML algorithms into the hardware equivalent, which customers can deploy in low cost, power efficient, and widely available chips (FPGAs). Algorithms are converted in just a few minutes, intelligently optimizing the FPGA configuration for best accuracy and execution speed which removes the need for expensive engineering resources and reduces development cycles from 3/6 months to a few minutes. AIccelerate enables customers to use complex and accurate models in real time applications for time-sensitive applications, like Autonomous Vehicles (AV) or Internet-of-Things (IoT).
• Concilio  is developing a therapeutic nanoparticle platform using a targeted polyelectrolyte complex micelle that delivers nucleotides to inflamed tissues with higher precision and enhanced efficacy. The modularity of the technology allows for the presentation of a variety of different cell targeting mechanisms on the micelle corona and to encapsulate various types of nucleotides in the micelle core thus making for a versatile platform to target numerous fibrotic and inflammatory diseases. Concilio is targeting cardiovascular indications – Arteriovenous fistula (AVF) failure and stenosis/restenosis as first to market.
• memQ is developing quantum repeaters using wafer scale platform based on erbium doped oxides to enable quantum communication between computers at distances orders of magnitude greater than what is available today. The relevant properties of their thin films are comparable to that of the bulk and can be fabricated into nanophotonic devices without degradation of qubit properties. These are devices with high Q and modest Purcell factor (a key metric of device quality) and has the engineerability of coherence time – a key metric for quantum memories. The device aims to allow for completely un-hackable communication protocols at distances spanning 1000s of kilometers. The company was the recipient of a $250,000 SAFE investment from the George Shultz Innovation Fund.